ACAD Stock Soared to a Four-Month High.
Acadia Pharmaceuticals shares are trading higher Wednesday after the company won summary judgement in a patent suit. Just then Acadia Surged upto 33% in regards to the news.
Acadia Pharmaceuticals (ACAD) notched a win in a patent battle Wednesday pertaining to its Parkinson's drug, Nuplazid. ACAD stock soared to a four-month high.
ACAD Stock: Cashing In On Nuplazid
Nuplazid is an important drug for Acadia. It's currently approved to treat patients with psychosis due to Parkinson's disease. In the September quarter, Nuplazid brought in $144.8 million in sales, accounting for more than 68% of total sales.
NASDAQ:ACAD is trading above the 50, 100, & 200-day moving average indicating a Bullish Bias.
Acadia
ACADIA Pharmaceuticals Inc - Biotech Run Up: Catalyst 3/12/23ACADIA Pharmaceuticals Inc. has a significant catalyst event scheduled for March 12th, 2023. After a prolonged decline, the stock has rebounded and broken out of a downward trend, indicating potential for upward movement. Investors should keep an eye on this biotech company as it approaches the catalyst date. Additional information on biotech catalysts can be found at biopharmcatalyst.com
Acadia pharmOn March 9, the FDA identified flaws in ACADIA's application for a new drug for Pimavanserin to treat hallucinations and delusions associated with psychosis and dementia.
By April 3, Acadia is likely to receive a full response letter from the FDA.
DRP approval of Pimavanserin is unlikely, but possible.
The stock bounced off 24.00, then 26.00 and 27.00. The figure W is formed
Accumulation for a jump takes 4 days, then a shot.
Risk 1: 5
ACAD (ACADIA PHARMACEUTICALS INC) BUY
ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low.
Price should bounce and fill in the Gap in the market
ACAD also filled its previous Buy gap from Sep 4th 2019
Title: Buy ACAD (ACADIA Pharmaceuticals)
Asset: Stock
Platform: Robinhood/WeBull/Etrade/ 401k account
Symbol: ACAD
Type: Buy Market Execution / Buy Limit
Time Frame: 1D
Entry Price 1: $26.50 ACTIVE
Entry Price 2: $22.50(PENDING)
Stop Loss: $19.50 (70 Pips)
Take Profit 1: $33.00 (70 pips)
Take Profit 2: $38.00 (140 pips)
Take Profit 3: $44.00 (200 pips)
Take Profit 4: $54.00 (300pips)
Status: 🏃🏽♂️Active🏃🏽♂️
Sector: Health Technology
Industry: Biotechnology
ACADIA Pharmaceuticals operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R Brann on July 16, 1993 and is headquartered in San Diego CA
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)buy ACAD
entry 1 $44.50 & entry 2 $42.50
sl $38.50
tp.1 $50.50 tp.2 $55.50 Tp.3 $60.00 Tp.4 $70.50 Tp.5 $80.00
many products releasing soon
Sector: Health Technology
Industry: Biotechnology
Employees: 503
ACADIA Pharmaceuticals , Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Valuation
Market Capitalization
8.373B
Enterprise Value ( MRQ )
5.922B
Enterprise Value/EBITDA ( TTM )
—
Total Shares Outstanding ( MRQ )
155.861M
Number of Employees
503
Number of Shareholders
26
Price to Earnings Ratio ( TTM )
—
Price to Revenue Ratio ( TTM )
22.1988
Price to Book (FY)
11.6201
Price to Sales (FY)
22.7131
Balance Sheet
Quick Ratio ( MRQ )
7.1997
Current Ratio ( MRQ )
7.2630
Debt to Equity Ratio ( MRQ )
0.0141
Net Debt ( MRQ )
-642.407M
Total Debt ( MRQ )
8.999M
Total Assets ( MRQ )
747.45M
Operating Metrics
Return on Assets ( TTM )
-0.3812
Return on Equity ( TTM )
-0.4504
Return on Invested Capital ( TTM )
-0.4450
Revenue per Employee ( TTM )
674107.3559
Price History
Average Volume (10 day)
1.571M
1-Year Beta
0.7491
52 Week High
58.7200
52 Week Low
21.5600
Dividends
Dividends Paid (FY)
0
Dividends Yield (FY)
0
Dividends per Share (FY)
0
Margins
Net Margin ( TTM )
-0.6499
Gross Margin ( TTM )
0.9621
Operating Margin ( TTM )
-0.6784
Pretax Margin ( TTM )
-0.6485
Income Statement
Basic EPS (FY)
-1.5982
Basic EPS ( TTM )
-1.5783
EPS Diluted (FY)
-1.5982
Net Income (FY)
-235.259M
EBITDA ( TTM )
-245.781M
Gross Profit ( MRQ )
86.899M
Gross Profit (FY)
327.732M
Last Year Revenue (FY)
339.076M
Total Revenue (FY)
339.076M
Free Cash Flow ( TTM )
-135.258M
ACAD ACADIA PHARMACEUTICALS INC 5X GAINS COMING SOON (HODL)many products releasing soon
Sector: Health Technology
Industry: Biotechnology
Employees: 503
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Valuation
Market Capitalization
8.373B
Enterprise Value (MRQ)
5.922B
Enterprise Value/EBITDA (TTM)
—
Total Shares Outstanding (MRQ)
155.861M
Number of Employees
503
Number of Shareholders
26
Price to Earnings Ratio (TTM)
—
Price to Revenue Ratio (TTM)
22.1988
Price to Book (FY)
11.6201
Price to Sales (FY)
22.7131
Balance Sheet
Quick Ratio (MRQ)
7.1997
Current Ratio (MRQ)
7.2630
Debt to Equity Ratio (MRQ)
0.0141
Net Debt (MRQ)
-642.407M
Total Debt (MRQ)
8.999M
Total Assets (MRQ)
747.45M
Operating Metrics
Return on Assets (TTM)
-0.3812
Return on Equity (TTM)
-0.4504
Return on Invested Capital (TTM)
-0.4450
Revenue per Employee (TTM)
674107.3559
Price History
Average Volume (10 day)
1.571M
1-Year Beta
0.7491
52 Week High
58.7200
52 Week Low
21.5600
Dividends
Dividends Paid (FY)
0
Dividends Yield (FY)
0
Dividends per Share (FY)
0
Margins
Net Margin (TTM)
-0.6499
Gross Margin (TTM)
0.9621
Operating Margin (TTM)
-0.6784
Pretax Margin (TTM)
-0.6485
Income Statement
Basic EPS (FY)
-1.5982
Basic EPS (TTM)
-1.5783
EPS Diluted (FY)
-1.5982
Net Income (FY)
-235.259M
EBITDA (TTM)
-245.781M
Gross Profit (MRQ)
86.899M
Gross Profit (FY)
327.732M
Last Year Revenue (FY)
339.076M
Total Revenue (FY)
339.076M
Free Cash Flow (TTM)
-135.258M
Acadia: Stochastic Oscillator UpturnStochastic Oscillator shows upturn for Acadia. Ichimoku Cloud support is very important in this case since today's session is not breaking it and could demonstrate positive trend force.
Please note that biotech companies present high uncertainty.
Disclosure: My articles contain statements and projections based on assumptions on capital markets, and therefore inherently subject to numerous risks and uncertainties.
Before buying or selling any stock you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.
I am not a financial advisor
Finding the upcoming support zone and the right time to sell/buyAcadia Pharmaceuticals has shown a downward swing during the past 2 business days or so. Before that it was on a very big run, which on my opinion was due to the high demand and the low buy/sell price. It will soon find support around the 32.67 up to the 38 zone (see the purple channel) based on the past downswing which i just stated. In the very near future it will also go on an run as big as the last one or maybe a little slower, but it will fall out again.
In my opinion it would be better to buy soon, sell some when it breaks the channel and then sell more when it reaches the climax of the channel.